Calibre What Science Can Do
This website contains promotional content about AstraZeneca Medications. This website is intended for healthcare professionals involved in the Acute Coronary Syndrome care pathway, such as hospital specialists from cardiology and cardiology-related departments, including A&E and elderly care, as well as GPs with a specific interest in cardiology, nurses, pharmacists and payers with budget responsibilities in cardiology.
Listen to expert authors on clinical studies
Approaches to patient selection for long-term dual antiplatelet therapy (DAPT)
Dr Marc Bonaca
Dr Marc Bonaca
Marc P. Bonaca, MD, MPH is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health which is an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research. CPC is a core resource of the University of Colorado research and community outreach infrastructure.
After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group. At Brigham and Women’s Hospital, Boston, MA, USA, he founded the Aortic Syndrome Program and served as the Medical Director of the Aortic Center. At the TIMI Study Group he was the Chairman of the TIMI Safety Desk and oversaw pharmacovigilance activities for more than 8 large, multinational clinical trials. At TIMI he was an investigator on the TRA2P-TIMI 50 trial, co-Principal Investigator of the PEGASUS-TIMI 54 trial, co-investigator and United States National Lead Investigator of the DECLARE-TIMI 58 trial, and Principal Investigator of the REAL-TIMI 63B trial. At TIMI he led investigation in multiple datasets evaluating vascular outcomes including major adverse limb events and venous thromboembolism. He is currently the Center Director and Clinical Project Principal Investigator of the Brigham and Women’s Hospital and Dartmouth Hitchcock Center in the American Heart Association Strategically Focused.
The PRECLUDE study
Prof Stefan James
Prof Stefan K James
Professor of Cardiology, Dept. of Medical Sciences, Scientific Director UCR, Uppsala University, Uppsala, Sweden
Stefan James is Professor of Cardiology at Uppsala University and Scientific Director of Uppsala Clinical Research Center. He is a Senior Interventional Cardiologist at Uppsala University Hospital Sweden. He graduated from Uppsala University Medical School and completed specialist training in Uppsala. He has previously held positions at the Karolinska Hospital, the University Hospital Örebro and Duke Clinical Research Institute, Duke University.
A Fellow of the European Society of Cardiology (ESC), Professor James is the Society’s official representative for the European Commission for Evaluation of Medical Devices. He co-chaired the previous and current 2017 ESC task force group for ST-elevation myocardial infarction, co-author of several of the recent European guidelines on ACS and revascularization.
Stefan James served as PI on steering committees for numerous international trials in cardiology including PLATO, Early-ACS trial, EVOLUTION, APPRAISE II, GUSTO IV-ACS, GEMINI and THEMIS. He is the chairman of the Swedish Coronary and Angioplasty registry and a member of the steering committee of SWEDEHEART and the Swedish TAVI registry. He has pioneered the concept of registry based randomized clinical trials and served as the study chair for large outcome trials TASTE and VALIDATE. His research has been published in over 200 peer-reviewed cardiology journals, and he is an editorial board member for the European Heart Journal, Circulation and American Heart Journal. Last year, he was named by Thomson Reuters as a ‘Highly Cited Researcher’, ranking him among the top 1% most cited in clinical medicine.